Cargando…

Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report

Recent advances in melanoma therapy have influenced the management of metastatic patients. Inhibitors of the BRAF/MEK/ERK signaling cascade have been proven highly effective in the metastatic disease although displaying different side effects. Here, we report a patient with BRAF V600E-mutated stage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orouji, Elias, Ziegler, Birgit, Umansky, Viktor, Gebhardt, Christoffer, Utikal, Jochen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2014
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603073/ https://www.ncbi.nlm.nih.gov/pubmed/25526431 http://dx.doi.org/10.1097/MD.0000000000000161

Ejemplares similares

Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response
por: Bernhardt, Mathias, et al.
Publicado: (2017)

The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
por: Umansky, Viktor, et al.
Publicado: (2016)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Resistance to Vemurafenib Can Be Reversible After Treatment Interruption: A Case Report of a Metastatic Melanoma Patient
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2014)

Tackling malignant melanoma epigenetically: histone lysine methylation
por: Orouji, Elias, et al.
Publicado: (2018)

Vemurafenib and Dabrafenib Downregulates RIPK4 Level
por: Madej, Ewelina, et al.
Publicado: (2023)

Efficacy and safety of acupuncture for chemotherapy-induced leukopenia: A systematic review and meta-analysis
por: Nian, Jiayun, et al.
Publicado: (2022)

HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma
por: Hüser, Laura, et al.
Publicado: (2020)

Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
por: Mistry, Hitesh B., et al.
Publicado: (2017)

Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma
por: Tahseen, Ahmed I., et al.
Publicado: (2018)

The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis
por: Zhou, Jian-Guo, et al.
Publicado: (2015)

Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!
por: Luherne, Camille, et al.
Publicado: (2019)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
por: Ghezzi, Marco, et al.
Publicado: (2020)

Systemic Therapy of Non-Resectable Metastatic Melanoma
por: Orouji, Azadeh, et al.
Publicado: (2010)

Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy
por: Kaehler, Katharina C., et al.
Publicado: (2016)

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
por: Daud, Adil, et al.
Publicado: (2017)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
por: Ozbay Kurt, Feyza Gul, et al.
Publicado: (2023)

Expression of Neural Crest Markers GLDC and ERRFI1 is Correlated with Melanoma Prognosis
por: Jäger, Katharina, et al.
Publicado: (2019)

New role of ID3 in melanoma adaptive drug-resistance
por: Sachindra,, et al.
Publicado: (2017)

Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib
por: Pinard, Camille, et al.
Publicado: (2017)

Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma
por: Orouji, Elias, et al.
Publicado: (2020)

Oncogenic Role of an Epigenetic Reader of m(6)A RNA Modification: YTHDF1 in Merkel Cell Carcinoma
por: Orouji, Elias, et al.
Publicado: (2020)

T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells
por: Granados, Karol, et al.
Publicado: (2020)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
por: Gao, Tianfu, et al.
Publicado: (2021)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Characteristics and prognosis of primary malignant melanoma of the esophagus
por: Chen, Hengchi, et al.
Publicado: (2020)

The combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients with resected breast cancer
por: Deng, Yunfu, et al.
Publicado: (2020)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Dabrafenib and its potential for the treatment of metastatic melanoma
por: Menzies, Alexander M, et al.
Publicado: (2012)

ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6
por: Vierthaler, Marlene, et al.
Publicado: (2022)

Prognostic factors for postoperative survival in melanoma patients with bone metastasis
por: Wang, Yucheng, et al.
Publicado: (2021)

Lymph Node Count After Preoperative Radiotherapy Is an Independently Prognostic Factor For Pathologically Lymph Node-Negative Patients With Rectal Cancer
por: Li, Qingguo, et al.
Publicado: (2015)

Primary cerebral malignant melanoma: A case report with literature review
por: Tang, Kai, et al.
Publicado: (2017)

Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma
por: Federico, Aniello, et al.
Publicado: (2020)

Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor–mutated lung adenocarcinoma
por: Li, Chi-Cheng, et al.
Publicado: (2020)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma
por: van der Westhuizen, Andre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eviqcdtcoo79lp5h152ptek2hh